Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC (NASIR-HCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03380130
Recruitment Status : Completed
First Posted : December 20, 2017
Last Update Posted : November 4, 2020
Sponsor:
Collaborators:
Sirtex Medical
Bristol-Myers Squibb
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 1, 2020
Actual Study Completion Date : November 4, 2020
Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):